<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113825</url>
  </required_header>
  <id_info>
    <org_study_id>AVB620-C-002</org_study_id>
    <nct_id>NCT03113825</nct_id>
  </id_info>
  <brief_title>Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery</brief_title>
  <official_title>An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avelas Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RRD International, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinipace Worldwide</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avelas Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic
      breast cancer undergoing surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent, nonmetastatic
      breast cancer undergoing either a lumpectomy with simultaneous sentinel lymph node biopsy
      (SLNB) or axillary lymph node dissection (ALND), or a mastectomy and simultaneous ALND.
      AVB-620 is a synthetic protease-activated peptide dye conjugate administered intravenously
      for the fluorescence detection and localization of potentially malignant tissue in primary
      tumor, tumor margins, or lymph nodes. A fluorescence image will be displayed on a monitor and
      will assist the surgeon to assess potentially cancerous tissue within the primary tumor site,
      tumor margins, or in lymph nodes which drain the primary tumor site.

      Eligible patients will receive a single dose of AVB-620 by IV infusion up to 24 hours prior
      to breast surgery.

      The study will evaluate the effect of timing of AVB-620 administration relative to surgery on
      the fluorescence and the accuracy of the AVB-620 imaging data to distinguish between
      malignant and nonmalignant tissues.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Period 1 will enroll approximately 35 patients to evaluate conditions to achieve maximal differences in fluorescent signals between malignant and nonmalignant tissue. Period 2 will enroll approximately 75 patients to test dosing and imaging conditions determined in Period 1 and accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the accuracy of AVB-620 imaging data to distinguish between malignant and nonmalignant tissues.</measure>
    <time_frame>1 month</time_frame>
    <description>Determine the accuracy of AVB-620 in correlating image-identified malignant breast or lymph node tissue with pathology findings in breast cancer patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of AVB-620 as assessed by incidence of adverse events and abnormal laboratory values.</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluate the safety and tolerability of a single AVB-620 infusion in women undergoing breast cancer surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify malignant tissue types that provide the most robust fluorescence response compared to non-malignant tissue.</measure>
    <time_frame>1 month</time_frame>
    <description>Measure fluorescence intensity differences between malignant and non-malignant tissue to identify best responding tissue type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate timing of AVB-620 administration on optical fluorescence characteristics</measure>
    <time_frame>1 month</time_frame>
    <description>Further evaluate the effect of the timing of AVB-620 administration on the optical fluorescence characteristics</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate imaging techniques and conditions</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluate the impact of changes in intraoperative imaging techniques and conditions in distinguishing malignant from nonmalignant tissue compared to pathological assessment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate methods for image analysis and display</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluate and refine methods and criteria by which images are analyzed and displayed</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate breast cancer patient suitability for AVB-620 imaging</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluate which breast cancer patients are most suitable for AVB-620 imaging</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine re-excision rates</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determine the planned and actual re-excision rates within 4 weeks after AVB-620 administration.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Primary Invasive Malignant Neoplasm of Female Breast</condition>
  <condition>Carcinoma Breast</condition>
  <condition>Breast Cancer Female</condition>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage III Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AVB-620 &amp; Investigational Imaging Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Investigational Imaging device</intervention_name>
    <description>Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.</description>
    <arm_group_label>AVB-620 &amp; Investigational Imaging Device</arm_group_label>
    <other_name>Fluorescent Imaging Camera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVB-620</intervention_name>
    <description>AVB-620 will be administered IV before the surgical procedure.</description>
    <arm_group_label>AVB-620 &amp; Investigational Imaging Device</arm_group_label>
    <other_name>Investigational Drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DCIS or Stage I-III primary invasive carcinoma of the breast

          -  Primary surgical treatment is lumpectomy + SLNB or ALND --or-- mastectomy + ALND

          -  Signed written informed consent

          -  At least 18 years of age

          -  ECOG performance status 0 to 2

          -  Life expectancy of at least 6 months

          -  Total bilirubin ≤ 2 mg/dL

          -  AST/SGOT and ALT/SGPT ≤ 2.5 X ULN

          -  Negative serum pregnancy test and using medically acceptable form of contraception if
             of child bearing potential

          -  LVEF within normal limits if patient received prior anthracycline therapy.

        Exclusion Criteria:

          -  Recurrent ipsilateral breast cancer

          -  Prior neoadjuvant chemo or biologic therapy for current breast cancer within 4 weeks
             prior to planned surgery.

          -  Open surgery in ipsilateral breast within 1 year.

          -  Prior malignancy, other than breast cancer, active within the last 6 months

          -  Radiation therapy to ipsilateral breast

          -  Abnormal cardiac rhythm not controlled with medication; Hx of stroke within 1 year; Hx
             of coronary events and/or heart failure within 1 year.

          -  Diagnosis of autoimmune disorder, including RA, SLE, or Sjogren's syndrome

          -  Hx of drug-related anaphylactic reactions, severe allergic reactions related to drug;
             active diagnosis of uncontrolled airway hyperactivity, uncontrolled asthma, or asthma
             requiring oral corticosteroids.

          -  Hx of drug-induced acute tubular necrosis.

          -  Chronic renal failure or current evidence of moderate to severe renal impairment.

          -  Current diagnosis of any other active or clinically significant nonbreast cancer

          -  Received systemic investigational drug within 6 weeks prior to AVB-620 administration
             or has received AVB-620 previously.

          -  Pregnant or breast feeding or plans to become pregnant within 6 months of AVB-620
             administration.

          -  Unresolved acute toxicity from prior anticancer therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with DCIS or Stage I-III breast cancer who are undergoing lumpectomies or mastectomies and sentinel lymph node biopsies or axillary lymph node dissection.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Chen, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Avelas Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melody Anderson, M.S.</last_name>
    <phone>858-750-4757</phone>
    <email>manderson@avelasbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christy Romanowski</last_name>
    <phone>949-229-6304</phone>
    <email>cromanowski@clinipace.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville -- Center for Breast Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sarah McLaughlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deanna Hogue</last_name>
      <phone>813-745-8304</phone>
      <email>deanna.hogue@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Gorham</last_name>
      <phone>813-745-4027</phone>
      <email>yvonne.gorham@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Catherine Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ameriangel Roman</last_name>
      <phone>718-405-8578</phone>
      <email>aromaner@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Sheldon Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maureen McEvoy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren L Hricik</last_name>
      <phone>216-844-5176</phone>
      <email>Lauren.Hricik@UHhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Cortez</last_name>
      <phone>216-896-1787</phone>
      <phone_ext>2</phone_ext>
      <email>Michelle.Cortez@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jill R Dietz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University, James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Gleich</last_name>
      <phone>614-688-7258</phone>
      <email>Erica.Gleich@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lynette Mesi</last_name>
      <phone>614-293-6669</phone>
      <email>Lynette.Mesi@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alicia Terando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aindrea 'Bree' Maddray, RN</last_name>
      <email>Aindrea.Maddray@RoperSaintFrancis.com</email>
    </contact>
    <investigator>
      <last_name>Paul Baron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>January 26, 2018</last_update_submitted>
  <last_update_submitted_qc>January 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast carcinoma</keyword>
  <keyword>DCIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

